- Initial data from a Phase 1/2 clinical trial, EVOLVE, evaluating Celgene's (NASDAQ:CELG) CAR-T therapy JCARH125 in heavily pretreated patients with relapsed/refractory multiple myeloma (MM) showed a treatment effect. The results were presented at ASH in San Diego.
- Participants received at least three prior lines of therapy, including an autologous stem cell transplant in eligible patients, a proteosome inhibitor, an immunomodulatory drug and an anti-CD38 monoclonal antibody. Dose escalation is ongoing.
- At data cutoff, 44 patients had received an infusion of JCARH125 in three dose-escalation arms. All had received a median of seven prior lines of therapies. 77% (n=34/44) had high-risk genetic profiles.
- The overall response rate (ORR) was 82% (n=36/44). Patients receiving the lowest dose [50x10(6) CAR T cells] showed an ORR of 79%, including a 43% complete response rate.
- On the safety front, 71% (n=31/44) experienced mild/moderate cytokine release syndrome (CRS) while 9% (n=4/44) experienced serious/life-threatening CRS. 18% (n=8/44) experienced mild/moderate neurological events while 7% (n=3/44) experienced serious/life-threatening neurological events. Other serious/life-threatening treatment-related adverse events were neutropenia (86%), anemia (50%), thrombocytopenia (43%) and infection (14%).
- Development is ongoing.
- #ASH18
- Now read: Momenta Pharma to delap filing U.S. marketing application for Humira biosimilar; shares down 1% after hours
Original article